Literature DB >> 17339569

Pathogenesis of chronic Chagas heart disease.

Jose Antonio Marin-Neto1, Edécio Cunha-Neto, Benedito C Maciel, Marcus V Simões.   

Abstract

BACKGROUND: Chagas disease remains a significant public health issue and a major cause of morbidity and mortality in Latin America. Despite nearly 1 century of research, the pathogenesis of chronic Chagas cardiomyopathy is incompletely understood, the most intriguing challenge of which is the complex host-parasite interaction. METHODS AND
RESULTS: A systematic review of the literature found in MEDLINE, EMBASE, BIREME, LILACS, and SCIELO was performed to search for relevant references on pathogenesis and pathophysiology of Chagas disease. Evidence from studies in animal models and in anima nobile points to 4 main pathogenetic mechanisms to explain the development of chronic Chagas heart disease: autonomic nervous system derangements, microvascular disturbances, parasite-dependent myocardial aggression, and immune-mediated myocardial injury. Despite its prominent peculiarities, the role of autonomic derangements and microcirculatory disturbances is probably ancillary among causes of chronic myocardial damage. The pathogenesis of chronic Chagas heart disease is dependent on a low-grade but incessant systemic infection with documented immune-adverse reaction. Parasite persistence and immunological mechanisms are inextricably related in the myocardial aggression in the chronic phase of Chagas heart disease.
CONCLUSIONS: Most clinical studies have been performed in very small number of patients. Future research should explore the clinical potential implications and therapeutic opportunities of these 2 fundamental underlying pathogenetic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17339569     DOI: 10.1161/CIRCULATIONAHA.106.624296

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  242 in total

1.  Arylimidamide DB766, a potential chemotherapeutic candidate for Chagas' disease treatment.

Authors:  Denise da Gama Jaén Batista; Marcos Meuser Batista; Gabriel Melo de Oliveira; Patrícia Borges do Amaral; Joseli Lannes-Vieira; Constança Carvalho Britto; Angela Junqueira; Marli Maria Lima; Alvaro José Romanha; Policarpo Ademar Sales Junior; Chad E Stephens; David W Boykin; Maria de Nazaré Correia Soeiro
Journal:  Antimicrob Agents Chemother       Date:  2010-05-10       Impact factor: 5.191

Review 2.  Chagas heart disease: report on recent developments.

Authors:  Fabiana S Machado; Linda A Jelicks; Louis V Kirchhoff; Jamshid Shirani; Fnu Nagajyothi; Shankar Mukherjee; Randin Nelson; Christina M Coyle; David C Spray; Antonio C Campos de Carvalho; Fangxia Guan; Cibele M Prado; Michael P Lisanti; Louis M Weiss; Susan P Montgomery; Herbert B Tanowitz
Journal:  Cardiol Rev       Date:  2012 Mar-Apr       Impact factor: 2.644

Review 3.  Cardiac involvement with parasitic infections.

Authors:  Alicia Hidron; Nicholas Vogenthaler; José I Santos-Preciado; Alfonso J Rodriguez-Morales; Carlos Franco-Paredes; Anis Rassi
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

4.  Highly conserved CDR3 region in circulating CD4(+)Vβ5(+) T cells may be associated with cytotoxic activity in Chagas disease.

Authors:  C A S Menezes; A K Sullivan; M T Falta; D G Mack; B M Freed; M O C Rocha; K J Gollob; A P Fontenot; W O Dutra
Journal:  Clin Exp Immunol       Date:  2012-08       Impact factor: 4.330

5.  Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

Authors:  S M Keating; X Deng; F Fernandes; E Cunha-Neto; A L Ribeiro; B Adesina; A I Beyer; P Contestable; B Custer; M P Busch; E C Sabino
Journal:  Int J Cardiol       Date:  2015-07-12       Impact factor: 4.164

6.  Vaccine-Linked Chemotherapy Improves Benznidazole Efficacy for Acute Chagas Disease.

Authors:  Kathryn Jones; Leroy Versteeg; Ashish Damania; Brian Keegan; April Kendricks; Jeroen Pollet; Julio Vladimir Cruz-Chan; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

7.  Prolonged dipyridamole administration reduces myocardial perfusion defects in experimental chronic Chagas cardiomyopathy.

Authors:  Denise Mayumi Tanaka; Luciano Fonseca Lemos de Oliveira; José Antônio Marin-Neto; Minna Moreira Dias Romano; Eduardo Elias Vieira de Carvalho; Antonio Carlos Leite de Barros Filho; Fernando Fonseca França Ribeiro; Jorge Mejia Cabeza; Carla Duque Lopes; Camila Godoy Fabricio; Norival Kesper; Henrique Turin Moreira; Lauro Wichert-Ana; André Schmidt; Maria de Lourdes Higuchi; Edécio Cunha-Neto; Marcus Vinícius Simões
Journal:  J Nucl Cardiol       Date:  2018-02-01       Impact factor: 5.952

8.  Chagas Cardiomyopathy in New Orleans and the Southeastern United States.

Authors:  Robert C Hsu; Joshua Burak; Sumit Tiwari; Chayan Chakraborti; Gary E Sander
Journal:  Ochsner J       Date:  2016

Review 9.  Vinculin and talin: focus on the myocardium.

Authors:  Alice Zemljic-Harpf; Ana Maria Manso; Robert S Ross
Journal:  J Investig Med       Date:  2009-12       Impact factor: 2.895

Review 10.  Pathology and Pathogenesis of Chagas Heart Disease.

Authors:  Kevin M Bonney; Daniel J Luthringer; Stacey A Kim; Nisha J Garg; David M Engman
Journal:  Annu Rev Pathol       Date:  2018-10-24       Impact factor: 23.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.